Source: iQoncept / Shutterstock
Immunovant (NASDAQ:IMVT) recently disclosed its performance for the fourth quarter of 2024.
- Immunovant reported an earnings per share of -52 cents, falling short of the forecasted -43 cents by analysts.
- The company did not generate any revenue during the quarter.
Article printed from InvestorPlace Media
©2024 InvestorPlace Media, LLC